Skip to content

Study · Non-randomized trial · 2000

9 results

Immunoactive Properties of Cerebrolysin.

Sotnikova NY, Gromova OA, Novikova EA, Burtsev EM

Russian journal of immunology : RJI : official journal of Russian Society of Immunology1 Apr 2000Cited by 1 (Europe PMC)

PMID12687163 (opens in a new tab)PepBankPUB-12687163
Publisher pageAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialMechanism

    In children with minimal cerebral dysfunction, cerebrolysin increased CD19(+) cell levels after treatment.

    In plain wordsIn children with minimal cerebral dysfunction, cerebrolysin increased CD19-positive immune cell levels after treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCD19(+) cells
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg · intramuscularly · one monthAs given in this study (human).

    Source sentences

    Summary
    The cerebrolysin administration resulted in an increase in the level of CD19(+) cells with a simultaneous normalization of serum IgG and IgA levels.
    1 context sentence
    Summary · context
    In children (aged 3-8 years old) with minimal cerebral dysfunction the immune status was studied before and after cerebrolysin administration in the dosage of 1 ml per 10 kg of child's weight, intramuscularly, within one month.
  2. 02HumanNon-randomized trialMechanism

    In children with minimal cerebral dysfunction, cerebrolysin normalized serum IgG levels after treatment.

    In plain wordsIn children with minimal cerebral dysfunction, cerebrolysin normalized serum IgG levels after treatment.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableSerum IgG
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg · intramuscularly · one monthAs given in this study (human).

    Source sentences

    Summary
    The cerebrolysin administration resulted in an increase in the level of CD19(+) cells with a simultaneous normalization of serum IgG and IgA levels.
    1 context sentence
    Summary · context
    In children (aged 3-8 years old) with minimal cerebral dysfunction the immune status was studied before and after cerebrolysin administration in the dosage of 1 ml per 10 kg of child's weight, intramuscularly, within one month.
  3. 03HumanNon-randomized trialMechanism

    In children with minimal cerebral dysfunction, cerebrolysin normalized serum IgA levels after treatment.

    In plain wordsIn children with minimal cerebral dysfunction, cerebrolysin normalized serum IgA levels after treatment.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableSerum IgA
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg · intramuscularly · one monthAs given in this study (human).

    Source sentences

    Summary
    The cerebrolysin administration resulted in an increase in the level of CD19(+) cells with a simultaneous normalization of serum IgG and IgA levels.
    1 context sentence
    Summary · context
    In children (aged 3-8 years old) with minimal cerebral dysfunction the immune status was studied before and after cerebrolysin administration in the dosage of 1 ml per 10 kg of child's weight, intramuscularly, within one month.
  4. 04HumanNon-randomized trialMechanism

    In children with minimal cerebral dysfunction, CD4(+) lymphocyte counts rose after cerebrolysin treatment.

    In plain wordsIn children with minimal cerebral dysfunction, CD4-positive immune cell counts rose after cerebrolysin treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCD4(+) lymphocytes
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg · intramuscularly · one monthAs given in this study (human).

    Source sentences

    Summary
    The count of CD4(+) lymphocytes has risen.
    1 context sentence
    Summary · context
    In children (aged 3-8 years old) with minimal cerebral dysfunction the immune status was studied before and after cerebrolysin administration in the dosage of 1 ml per 10 kg of child's weight, intramuscularly, within one month.
  5. 05HumanNon-randomized trialMechanism

    In children with minimal cerebral dysfunction, cerebrolysin normalized the relative CD16(+) natural killer cell count after treatment.

    In plain wordsIn children with minimal cerebral dysfunction, cerebrolysin normalized the relative count of natural killer cells after treatment.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableRelative CD16(+) cell count
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg · intramuscularly · one monthAs given in this study (human).

    Source sentences

    Summary
    Normalization of a relative count of CD16(+) cells (NK) was noted after cerebrolysin therapy.
    1 context sentence
    Summary · context
    In children (aged 3-8 years old) with minimal cerebral dysfunction the immune status was studied before and after cerebrolysin administration in the dosage of 1 ml per 10 kg of child's weight, intramuscularly, within one month.
  6. 06HumanNon-randomized trialMechanism

    In children with minimal cerebral dysfunction, lymphocyte CD25 expression reached control group parameters after cerebrolysin treatment.

    In plain wordsIn children with minimal cerebral dysfunction, immune cell CD25 expression reached control group levels after cerebrolysin treatment.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableCD25 expression
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg · intramuscularly · one monthAs given in this study (human).

    Source sentences

    Summary
    Expression of activation markers (CD25 and HLA DR) in total population of lymphocytes parallelly changed, achieving the parameters of the control group without any changes in expression of CD95 molecule.
    1 context sentence
    Summary · context
    In children (aged 3-8 years old) with minimal cerebral dysfunction the immune status was studied before and after cerebrolysin administration in the dosage of 1 ml per 10 kg of child's weight, intramuscularly, within one month.
  7. 07HumanNon-randomized trialMechanism

    In children with minimal cerebral dysfunction, lymphocyte HLA DR expression reached control group parameters after cerebrolysin treatment.

    In plain wordsIn children with minimal cerebral dysfunction, immune cell HLA DR expression reached control group levels after cerebrolysin treatment.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableHLA DR expression
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg · intramuscularly · one monthAs given in this study (human).

    Source sentences

    Summary
    Expression of activation markers (CD25 and HLA DR) in total population of lymphocytes parallelly changed, achieving the parameters of the control group without any changes in expression of CD95 molecule.
    1 context sentence
    Summary · context
    In children (aged 3-8 years old) with minimal cerebral dysfunction the immune status was studied before and after cerebrolysin administration in the dosage of 1 ml per 10 kg of child's weight, intramuscularly, within one month.
  8. 08HumanNon-randomized trialMechanism

    In children with minimal cerebral dysfunction, CD95 expression did not change after cerebrolysin treatment.

    In plain wordsIn children with minimal cerebral dysfunction, immune cell CD95 expression did not change after cerebrolysin treatment.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeCD95 expression
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg · intramuscularly · one monthAs given in this study (human).

    Source sentences

    Summary
    Expression of activation markers (CD25 and HLA DR) in total population of lymphocytes parallelly changed, achieving the parameters of the control group without any changes in expression of CD95 molecule.
    1 context sentence
    Summary · context
    In children (aged 3-8 years old) with minimal cerebral dysfunction the immune status was studied before and after cerebrolysin administration in the dosage of 1 ml per 10 kg of child's weight, intramuscularly, within one month.
  9. 09LabIn vitro (cells)Mechanism

    In vitro, cerebrolysin mainly activated T helper cells.

    In plain wordsIn cells, cerebrolysin mainly activated T helper immune cells.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseT helper activation in vitro
    Study

    n: not reported in source

    In vitro T helper cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Under the cerebrolysin influence the activation mainly of T helpers could be observed in vitro.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.